Partnership and Collaboration - Berry Genomics will leverage PacBio's Vega system to develop long-read sequencing-based solutions for carrier, prenatal, and newborn screening programs in China and other markets [1] - Berry Genomics will build on the Vega platform to deliver solutions tailored to the characteristics of its clinical customers and the populations they serve [2] - Berry Genomics has committed to purchasing more than 50 Vega units as part of its agreement with PacBio [2] Technology and Product Development - The Vega system is PacBio's first benchtop long-read sequencing platform, offering exceptional data accuracy with HiFi technology and fast turnaround time [4] - Vega delivers the functionality of PacBio's high-throughput Revio system in a compact, lower-throughput benchtop platform, making it suitable for laboratories with limited space and sample volumes [4] - Berry Genomics will take the resulting instrument through the NMPA regulatory review process in China and support additional product registrations in other markets [2] Market and Application Focus - Next-generation sequencing technology has shown great potential in understanding genetic diseases and interpreting the human genome to benefit human health [3] - Small to medium-sized laboratories in China require genomics equipment that is compact, affordable, and capable of processing smaller sample volumes quickly [3] - Berry Genomics aims to provide best-in-class genomics services to clinical labs, unlocking new research opportunities and expanding the application of long-read sequencing technology [3][8] Company Background - PacBio is a premier life science technology company specializing in advanced sequencing solutions, including HiFi long-read sequencing and SBB short-read sequencing technologies [5] - Berry Genomics, established in 2010 and listed on the A-share main board in 2017, focuses on transforming genetic testing technology into clinical applications, particularly in reproductive health, genetic disease testing, and oncology [7][8]

Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day. The stock's change was more than the S&P 500's daily loss of 1.11%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq decreased by 1.89%.Heading into today, shares of the maker of genetic analysis technology had lost 8.72% over the past month, lagging the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7% in that time.The investment c ...

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 ...

I'm an investment analyst with clinical experience in healthcare and an MBA, expanding my focus from biotech to a range of sectors. I've had the privilege of sharing my insights on Seeking Alpha since 2017, emphasizing financial modeling techniques like DCF analysis to identify underlying assumptions in stock valuations. I provide scenario-based forecasts to help readers gauge reasonable outcomes. Influenced by works like Superforecasting and Antifragile, I advocate for disciplined risk management through a ...

Table of Contents UNITED STATES (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 | --- | --- | |------------------------|----------------------------------------------------------------------------------------------------------------------------------| | Washington, D.C. 20549 | SECURITIES AND EXCHANGE COMMISSION _____________________________________________________________________________________________ | ...

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 5:00 PM ET in Rancho Palos Verdes, CAWolfe Research Healthcare Conference on Tuesday, November 19, 2024, at 3:30 PM ET in New York, NYStephens Annual Investment Conference on Wednesday, Nov ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted third-quarter 2024 loss per share of 17 cents, narrower than the year-ago quarter’s loss of 27 cents. The adjusted loss per share beat the Zacks Consensus Estimate by 15%.The company’s GAAP loss per share was 22 cents in the quarter, narrower than the year-ago period’s loss of 26 cents.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenues in DetailPacBio registered revenues of $40 mi ...

| --- | --- | --- | |-----------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | PacBio Q3 2024 Earnings | | | | | | | | Presentation | | | | November 7, 2024 Third Quarter 2024 Earnings Call | | | | | | | | | | | | | | | | | | | 1 Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in add ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Brennan - TD Cowen Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Securities Madeline Mollman - Wolfe Research ...

Pacific Biosciences of California (PACB) reported $39.97 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 28.2%. EPS of -$0.17 for the same period compares to -$0.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $41.9 million, representing a surprise of -4.60%. The company delivered an EPS surprise of +15.00%, with the consensus EPS estimate being -$0.20.While investors scrutinize revenue and earnings changes year-over-year and h ...